Enanta Pharmaceuticals | ENTA - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 3.61B 2.92B 2026-06
Amgen USD 2.38B 556M 2026-06
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD -194.28M 61.55M 2026-06
AstraZeneca USD 2.51B 573M 2026-06
BioCryst Pharmaceuticals USD 78.4M 167.45M 2026-06
Biogen USD 97.5M 222M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD -10.5B 12.52B 2026-06
GlaxoSmithKline GBP 435M 1.3B 2026-06
Halozyme Therapeutics USD 229.91M 79.86M 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Immunic USD -19.3M 6.28M 2025-12
Incyte USD 585.6M 282.27M 2026-06
Insmed USD -13.24M 150.32M 2026-06
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
J&J USD 5.53B 299M 2026-06
Karyopharm Therapeutics USD -22.39M 79.81M 2026-03
Ligand Pharmaceuticals USD 48.51M 61.85M 2026-06
Merck USD -1.34B 2.9B 2026-06
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Novartis USD 3.26B 108M 2026-06
Novavax USD 17.53M 219.91M 2025-12
Pfizer USD -248M 2.94B 2026-06
PTC Therapeutics USD -2.81M 132.16M 2026-03
Roche Holding CHF 6.87B 1.4B 2026-06
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Vertex Pharmaceuticals USD 1.1B 68.4M 2026-06